Related Experiment Video
Updated: Jun 19, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus
Isabelle Thuret1, Marie-Laure Chaix, Catherine Tamalet
1Service d'Hématologie Pédiatrique, CHU Timone, Marseille, France.
Abstract:
Twelve heavily pretreated, perinatally infected adolescents in virological failure were treated with a combination of raltegravir, r-darunavir and etravirine, as part of an expanded access program in France. After a 12-month median follow-up, viral load was <400 copies/ml in 11 (<50 in six). No grade > 2 side effects were recorded. Additional data and marketing authorizations are awaited, but preliminary results in adolescents with extensive multidrug resistant virus are encouraging.
Related Concept Videos
Retrovirus Life Cycles
Antiviral Nucleoside Inhibitors
Pharmacokinetics in Pediatric Patients: Drug Excretion
Retroviruses
Subviral Agents
Respiratory Syncytial Virus Disease

